Abbott Laboratories (ABT)

Total return at 5 years: 3.6%/year = 0.6% appreciation + 3.0% dividend. The target price ($105) is ex-dividend; the $16 in dividends collected over 5 years are added separately.

The methods disagree: one places the value today above the price ($102) and the other below.

Today — expensive, no margin of safety: at $102 trades ~4.1% above its value discounted to today (~$98); the expected return does not even reach the risk-free rate (4.5%).

At 5 years — Preserva valor: the target price ($105) plus dividends yield just enough to preserve nominal capital, below the required 4% floor.

The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$62.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($102) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The market discounts less growth (-3.1%/year) than we project (7.0%/year) → if the base case holds, there is margin: perception is more pessimistic than the estimated reality.

That growth implies ~$7.9 bn of owner earnings in year 5 (vs ~$12.9 bn of our base case). It recalculates if the DCF assumptions are edited.

Year-by-year projection of the selected scenario. From each year, two versions of the flow are derived: growth FCF (operating flow − total capex, the cash surplus) and maintenance FCF (the owner earnings: what the business yields if it only sustains its capacity). The flow is returned almost in full (dividend + buyback) or redeployed into the operation, so that EV stays roughly flat and multiples compress because the metric grows, not because of cash accumulation. The valuation is done on NOPAT (EV/NOPAT). In edit mode, revenue, margins, capex, and exit multiples can be adjusted.

Rolling grid: year-0 is the real TTM to Jun-2026 (revenue $46,585M = FY2025 $44,328M + first half 2026 $23,757M − first half 2025 $21,500M). Abbott is diversified healthcare: Medical Devices (48% of revenue, the engine — FreeStyle Libre CGM, +9.5% comparable in the second quarter), Diagnostics (which since March 2026 includes the Cancer Diagnostics business contributed by Exact Sciences), Nutrition and Emerging-Markets Pharma. It is valued at the enterprise level on an adjusted basis, not GAAP, which is depressed by the amortization of acquisition intangibles (St. Jude, Alere, Exact Sciences), which is non-economic; FY2024 is also inflated by a one-time tax reversal. The year-0 operating margin (21.1%) is the normalized TTM: on GAAP operating income of $7,346M, the intangible amortization ($1,922M) and the charges tied to the Exact Sciences closing ($580M, including accelerated stock-based compensation from Exact's plans) are added back; restructuring and the other specified items stay in, so the base is stricter than the adjusted operating income the company publishes (22.9% of the same TTM). Year 1 (+11.9%) anchors on guidance: on the pro forma sales the 10-Q publishes for 2025 (~$23,000M in the first half, i.e. a combined annual base of ~$49,000M), the guided comparable growth range of 6.5% to 7.5% gives $52,200M-52,700M and the model takes the floor. Exit multiple 18× (adverse 15× / favorable 20.5×): a disciplined premium over pharma for the absence of a patent cliff and continuous glucose monitoring's secular growth, with a discount for the infant formula litigation and the new leverage. The multiple applies to adjusted after-tax operating income, which is pre-interest, so net debt of ~$25,900M (gross debt $32,608M against $6,714M of cash and investments) enters the bridge and funding is charged once. No projected share-count path: the buyback is small (the priority is the dividend, 54-year king).

Today's elevated multiple is the price of growth: if the business grows, the entry point cheapens on its own going forward (the metric grows while EV stays roughly flat). The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—, so the value curve shows whether value creation is concentrated in the early or the later years. The required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $105 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $102, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $105 in 5 years plus $16 of dividends collected (the dividend adds to the return, not to the price) and a required return of 4.5% annually, the maximum to pay today is $98. Against the current market price ($102), the margin of safety is -4.1% (trades above the maximum → a premium is paid) and the total return at that price would be 3.6% annually.

• Multiple vs the band. Entry multiple ~27× on adjusted after-tax operating income — below the middle of the quality medical-technology band (16-22×). Reasonable, not expensive.
• The 2026 decline. The stock fell on the NEC litigation, on the leverage left by the Exact Sciences acquisition and on a soft organic first half. It generated a genuine discount against the archetype's band.
• Margin of safety. 5-year base ~$105 vs price ~$102 → total return +4%/year (the dividend a part). A modest discount; the asymmetry is balanced-to-favorable (the litigation remainder and the Exact integration are the risk, the litigation getting on track the upside).

• ✕ ROIC exceeds the cost of capital (~10%)
• ✓ CFROIC backs up the ROIC (100%, cash vs. accruals)
• ✓ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• ROIC vs the 10% bar. ROIC ~11% — above the bar (the operating business, especially Devices with its 33.7% margin, is high-return; goodwill from acquisitions dilutes it).
• Quality of cash. Free cash flow (~$7.4bn) is solid. SBC (small) stays expensed. Adjusted earnings add back only the non-economic intangible amortization.
• Leverage after the Exact acquisition. Gross debt went from $12,929M at year-end 2025 to $32,608M at Jun-30-2026 ($20,000M issued in March to buy Exact Sciences), against $6,714M of cash and investments; AA-/Aa3 rating before the deal, with a committed $5,000M backstop facility.

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

Abbott's engine is Medical Devices (48.2% of FY2025 revenue), and within it the FreeStyle Libre CGM — a secular wave of continuous glucose monitoring, with Lingo expanding it into wellness, which grew +9.5% comparable in the second quarter of 2026. Structural heart (TriClip, Navitor) and electrophysiology (Volt PFA, +13.4% comparable) grow at double digits. The decline in COVID testing ($1,600M in 2023 → $297M in 2025) has largely been absorbed, though Diagnostics faces challenging market conditions in China. The Exact Sciences acquisition, closed in March 2026, added the Cancer Diagnostics business ($919M in the second quarter). The dividend (54-year king) plus a small buyback return cash; growth is reinvested in research and development and in the Exact integration.

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (30-jun-2026): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• Real, not nominal. CGM growth (+17.4% ex-FX) + structural heart (double digits) is real and secular. The consolidated figure (+5.7% reported) gets diluted by Nutrition/Diagnostics.
• Growth engine. The FreeStyle Libre CGM and Lingo (the secular engine, +9.5% comparable in the second quarter) + structural heart and electrophysiology. Cologuard adds in since March 2026. But weak Nutrition (−5.6%) and a soft first half temper it.
• Reacceleration. The first half of 2026 ran below the +6.5-7.5% guidance — the second-half reacceleration is what needs to be confirmed.

• Relevant in 10 years (recurrence). Diversified healthcare (CGM, installed-base diagnostics, nutrition, brands) is defensive and recurring. CGM is a secular wave. High recurrence.
• Pricing power. Solid in devices plus diagnostics (installed base), more limited in Nutrition (competition) and emerging-markets pharma (generics). The gross margin improves (52.6%).
• Moat and its direction. A wide but uneven moat; direction stable on a consolidated basis (Devices widens, Diagnostics erodes, offsetting each other). Diversification stabilizes but dilutes growth.
• Devices concentration. Medical Devices is 48% of revenue and nearly all the growth; if CGM or structural heart stumble, the consolidated figure suffers.

Not all debt is equal: only the structural needs refinancing; the rest is operational (self-liquidating).

Structural debt is what is exposed to the contraction phase of the cycle; operational debt (leases, matched funding) self-liquidates with the business.

• ✓Leverage (net debt / EBITDA)Net cash $0 bn
• ✓Interest coverage (EBIT / interest)12.9x
• –Liquidity (current ratio)no data
• ✓Cash quality (CFROIC vs ROIC)CFROIC backs 100% of ROIC
• ✕Value creation (ROIC − 10% bar)-0pp
• ✓Malinvestment test (capex vs incremental ROIC)Capex/D&A 1.4x
• !Float / working capitalConsumes cash $0.4 bn (positive WC)
• ✓Dilution (SBC % of revenue + shares)SBC 1.5% of revenue

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Leverage. Gross debt $32,608M at Jun-30-2026 ($29,603M long-term + $3,005M current) against $6,714M of cash and investments, after issuing $20,000M in March to buy Exact Sciences; AA-/Aa3 rating before the deal. TTM operating cash flow ($9,905M) comfortably covers the dividend and capex.
• Cash generation. Operating cash flow ~US$9.6bn (vs US$8.6bn in 2024); capex ~US$2.2bn/year → free cash flow ~US$7.4bn. Comfortably covers the dividend. SBC is small.
• Dividend sustainability. 54-year dividend king; free cash flow covers the dividend with comfortable headroom. Solid — capital allocation's priority #1.

Who owns the shares — the alignment and whether there is a controlling shareholder.

• Skin in the game. Ford, a 30-year veteran, holds 469,508 shares + 2.27M exercisable options above the requirement (6× base salary); dispersed ownership (no founder control). Reasonable alignment.
• Capital allocation. Dividend-led (54-year king) + the largest acquisition in nearly a decade (Exact Sciences, ~$20,600M, closed in March 2026 and debt-financed). Small buyback. The return on that acquisition is the open test.
• Execution / integrity. Ford grew CGM into Abbott's engine. The live tests: closing and integrating Exact + handling the NEC litigation + the Department of Justice investigation (Sturgis) + the tax disputes with the IRS and Malaysia.

• The stock fell on the infant formula (NEC) litigation: in May 2026 the Missouri Court of Appeals affirmed the $495M Gill case verdict, on a balance sheet that carries no reserve for these cases — a sale motivated by fear of a large, unreserved verdict. On Aug-20-2026 Abbott settled that case and claims from ~2,000 people for ~$670M in aggregate, against the ~$600M it would have paid for Gill alone with interest.
• The Exact Sciences acquisition, closed on Mar-23-2026 for ~$20,600M, dilutes earnings in the first year on the interest from the $20,000M of debt issued to fund it and took gross debt from $12,929M to $32,608M — the market is discounting the leverage and the execution of the integration.
• Comparable growth in the first half of 2026 (+4.3%) ran below the annual guide of 6.5% to 7.5% on Nutrition's weakness (−5.6%) and challenging conditions in Diagnostics in China — a short-term stumble that added to the sell-off.

Abbott has a genuine source of discount: the combination of a motivated sale (fear of the unreserved NEC litigation) plus the leverage from a large acquisition brought it to trade at ~27× on adjusted after-tax operating income, below its archetype's band. The gap between perception and reality: the market is discounting the worst case of the litigation, and what is verifiable points the other way — Abbott wins in the federal forum (three bellwether cases on summary judgment, the first affirmed by the Seventh Circuit in July 2026), the August settlement resolved the most expensive case for an amount roughly in line with what it already owed on that case alone, and the secular engine keeps growing. The discount is not huge (comparable growth is modest and the risks are real, including ~1,700 unreserved remaining lawsuits and active tax disputes with the IRS and Malaysia), but it is real — and the litigation getting on track is an option on a quality business.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at -5%/year (-21% total): the margin of safety protects the downside. The bull (+9%/year, +55% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• NEC litigation. The central disconfirmer: necrotizing enterocolitis claims in premature infants, with no accounting reserve at Jun-30-2026. The Missouri Court of Appeals affirmed the $495M Gill case verdict in May, which Abbott settled in August together with ~2,000 claims for ~$670M; ~1,700 lawsuits remain, involving ~12,700 infants. Abbott wins in the federal forum (the three bellwether cases). A large, unreserved risk.
• Department of Justice (Sturgis). Criminal investigation since Nov-2022 + Department of Justice partial intervention (Nov-2025) in a private whistleblower's civil suit + an additional multi-state lawsuit (Dec-2025), all related to the Sturgis infant-formula plant.
• Leverage after Exact Sciences. The Exact Sciences acquisition ($20,000M of debt issued in March 2026) took gross debt to $32,608M from $12,929M, with $351M of interest expense in the second quarter alone. AA-/Aa3 rating before the deal.
• Organic slowdown. The first half of 2026 ran below the +6.5-7.5% guidance (weakness in Nutrition, challenging conditions in Diagnostics in China) — if it doesn't reaccelerate, earnings growth is lower.

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  Fails the quality gate: ROIC barely matches the 10% bar (the market's opportunity cost), no excess return.

• Peter Lynch Growth at a reasonable price (GARP)

  A stalwart growing 7% at a multiple/growth of 3.8 → expensive for its growth.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Earnings yield 6% (EBIT/EV) + ROIC 10% → falls outside the Magic Formula.

• Howard Marks Perception vs reality + cycle

  The price discounts -3% vs our 7%: perception is more pessimistic than reality, with an identified source of the discount.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor -8%/yr over 5y (material loss) → risk of permanent capital loss.

• Pat Dorsey Moat strength (Five Rules)

  A wide moat, stable; sources: intangibles, switching costs, cost advantage, efficient scale → passes the Five Rules.

• Aswath Damodaran Expectations implied by the price

  Justifying the price requires discounting -3%, within what we project (7%) — the story squares with the numbers.